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Abstract
Aim—The aim of this study was to compare the expression of 22 chemokines and cytokines in
gingival crevicular fluid (GCF) from smokers and non-smokers with periodontitis and
periodontally healthy control subjects.
Materials and Methods—Forty subjects with generalized severe chronic periodontitis (20
smokers and 20 non-smokers) and 12 periodontally healthy control subjects participated in this
study. Four diseased and 2 healthy sites were selected from each of the periodontitis subjects. GCF
samples were collected and cytokines analyzed utilizing a multiplexed immunoassay (Luminex®).
Statistical analyses employed non-parametric tests including the Mann-Whitney and Wilcoxon
matched-pairs signed-rank tests.
Results—Compared to healthy control subjects, GCF in subjects with chronic periodontitis
contained significantly higher amounts of IL-1α, IL-1β, IL-6, IL-12 (p40) (pro-inflammatory
cytokines); IL-8, MCP-1, MIP-1α, RANTES (chemokines); IL-2, IFN-γ, IL-3, IL-4 (Th1/Th2
cytokines); IL-15 (regulator of T-cells and NK cells). Smokers displayed decreased amounts of
pro-inflammatory cytokines (IL-1α, IL-6, IL-12 (p40)), chemokines (IL-8, MCP-1, MIP-1,
RANTES) and regulators of T-cells and NK cells (IL-7, IL-15).
Conclusions—Periodontitis subjects had significantly elevated cytokine and chemokine
profiles. Smokers exhibited a decrease in several pro-inflammatory cytokines and chemokines and
certain regulators of T-cells and NK-cells. This reflects the immunosuppressant effects of smoking
which may contribute to an enhanced susceptibility to periodontitis.
Keywords
Smoking; periodontal disease; immune response; periodontitis/etiology; chronic periodontitis;
gingival crevicular fluid
Correspondence address: Georgia K. Johnson, DDS, MS; Professor and Head, Periodontics; College of Dentistry; DSB S452; 801
Newton Road; University of Iowa; Iowa City, IA 52242. Phone: 319-335-7407. FAX: 319-335-7239. georgia-johnson@uiowa.edu.
Conflict of interest and source of funding statement: The authors declare that they have no conflict of interests.
NIH Public Access
Author Manuscript
J Clin Periodontol. Author manuscript; available in PMC 2012 March 1.
Published in final edited form as:














Gingival crevicular fluid (GCF) in periodontitis subjects contains inflammatory cells, serum
proteins, bacteria, tissue breakdown products, enzymes, antibodies, complement, and
numerous inflammatory mediators (Cimasoni, 1983, Armitage, 1996). GCF volume
increases with periodontal inflammation (Loe and Holm-Pedersen, 1965, Oliver et al.,
1969), its flow rate increasing up to 30-fold in periodontitis sites compared to healthy sites
(Goodson, 2003). Collection of GCF is relatively noninvasive, making it a convenient tool
to evaluate markers of periodontal inflammation. The magnitude of inflammation can be
determined by measuring pro-inflammatory and immuno-regulatory cytokines and
chemokines in the GCF. Sites with clinical inflammation have elevated levels of many
different cytokines and chemokines including interleukin (IL)-1, IL-6, IL-8, and tumor
necrosis factor (TNF)-α that play an important role in the pathogenesis of the periodontitis
(Genco, 1992).
Cigarette smoking is a significant risk factor for periodontitis (Bergstrom and Preber, 1994).
Tobacco use induces alterations in microbial populations (Zambon et al., 1996, Umeda et
al., 1998, Haffajee and Socransky, 2001, van Winkelhoff et al., 2001, Eggert et al., 2001). It
is well accepted that smoking alters the host response, including vascular function,
neutrophil/monocyte activities, adhesion molecule expression, antibody production, as well
as cytokine and inflammatory mediator release (Barbour et al., 1997, Kinane, 2000, Palmer
et al., 2005, Ryder, 2007). These changes likely contribute to the negative impact of
smoking on the reparative and regenerative potential of the periodontium.
In cell culture systems, nicotine treatment increases production of IL-6 by murine
osteoblasts (Kamer et al., 2006) and fibroblasts (Wendell and Stein, 2001) and IL-1 by
keratinocytes (Johnson and Organ, 1997). Although these studies are useful in understanding
mechanisms of tobacco related periodontal destruction, nicotine is only one component of
tobacco. In addition, there are a variety of cell types involved in the in vivo response to
smoking. GCF provides an avenue to evaluate the multiple effects of smoking on the host
response in the periodontium. The existing studies have focused on smoking’s impact on a
limited number of pro-inflammatory cytokines and chemokines. Smokers have elevated
GCF levels of TNF-α (Bostrom et al., 1998) and IL-8 (Giannopoulou et al., 2003a,
Giannopoulou et al., 2003b). In other studies, smoking decreases the levels of certain
cytokines in GCF, such as IL-1β, IL-1 receptor antagonist (ra) (Rawlinson, Grummitt et al.
2003), IL-1α (Petropoulos, McKay et al. 2004), and IL-8 (Kamma et al., 2004), although
others have shown no effect on IL-1β amounts (Giannopoulou et al., 2003b, Bostrom et al.,
2000). Smoking’s effect on a wider spectrum of biomarkers in GCF has not been well
characterized. Therefore, this study evaluated the impact of smoking on a panel of
biomarkers.
GCF was obtained from smokers and nonsmokers with generalized severe chronic
periodontitis and periodontally healthy controls. Twenty two different biomarkers were
evaluated: Th1 cytokines (IL-2, IL-12(p70), and interferon (IFN)-γ); Th2 cytokines (IL-3,
IL-4, IL-5, IL-10, and IL-13); pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, granulocyte
macrophage colony stimulating factor (GM-CSF), TNF-α, and IL-12(p40)); chemokines
(IL-8, interferon inducible protein-10 (IP-10), macrophage chemotactic protein-1 (MCP-1),
macrophage inflammatory protein (MIP)-1α, regulated on activation normal T cell
expressed and secreted (RANTES) and Eotaxin); and regulators of T and natural killer cell
activation and proliferation (IL-7 and IL-15). Through the evaluation of this extensive panel
of GCF biomarkers, this study aimed to characterize the impact of smoking and periodontitis
on the host response.
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Fifty-two subjects, including 40 periodontally diseased subjects (20 smokers and 20 non-
smokers) and 12 periodontally healthy non-smokers, participated in this study (Table 1). The
mean age of all 52 subjects was 55 ± 9.6 years. All subjects were Caucasian with the
exception of one Asian and one Hispanic subject. Periodontally diseased subjects had a
diagnosis of generalized severe chronic periodontitis (> 30% of sites with a clinical
attachment level (CAL) and probing depth (PD) ≥ 5 mm) (Table 2).
Subjects had not received periodontal therapy for four months preceding their participation
in the study. Smokers were enrolled if they regularly smoked ≥20 cigarettes per day, and
non-smokers were characterized as not having smoked one hundred or more cigarettes in
their lifetime. Periodontally healthy subjects included nonsmokers with CAL and PD ≤ 3
mm and bleeding on probing (BOP) at ≤10% of sites. To participate in the study, all subjects
were in good general health. Subjects were excluded from participating if they were
pregnant or had a history of diabetes or intake of medication, such as antibiotics and anti-
inflammatory agents, due to their possible effects on the microbial flora and/or the immune
or inflammatory response, for six months prior to the study.
Subject selection and data collection were performed in the Department of Periodontics at
the College of Dentistry, University of Iowa. Written informed consent was obtained from
each subject, and the study protocol was approved by the University of Iowa Institutional
Review Board.
Site selection
Two diseased (PD and CAL ≥5 mm with BOP) and two healthy sites (PD and CAL ≤3mm
with no BOP) were identified in each of the 40 periodontitis subjects and two healthy sites
were identified in the 12 periodontally healthy control subjects. The diseased and healthy
sites in the 20 smokers were identified as SD and SH, respectively. In the 20 nonsmokers,
the diseased and healthy sites were designated as ND and NH, respectively (Table 2). Four
healthy sites were sampled from the twenty periodontally healthy, non-smoking individuals
and classified as (Con).
GCF collection
GCF collection took place at a subsequent visit following the initial examination. Prior to
GCF sampling, the individual tooth site was isolated with cotton rolls, supragingival plaque
was carefully removed and the site was gently air-dried with the air syringe. A paper strip
(Periopaper, Amityville, NY, USA) was inserted into the crevice 1–2 mm for 30s. The GCF
volume was determined based on measurements made using a Periotron 8000 (Oraflow Inc.,
Plainview, NY, USA) as recently described (Thunell et al., 2010). In cases of visible
contamination with blood, the strips were discarded and new sites sampled. Strips from each
subject were placed into labeled tubes containing 300 µl 0.01 M PBS, pH 7.2 and protease
inhibitor (Complete Mini, protease inhibitor cocktail tablets, Roche Applied Science, IN,
USA). After shaking for 20 min, the strips were removed and the eluates centrifuged for 5
min at 5,800 × g to remove plaque and cellular elements. The samples were frozen at −80°
C until further analysis.
Cytokine and chemokine analysis
Th1 cytokines (IL-2, IL-12(p70), and IFN-γ), Th2 cytokines (IL-3, IL-4, IL-5, IL-10, and
IL-13), proinflammatory cytokines (IL-1α, IL-1β, IL-6, GM-CSF, TNF-α, and IL-12(p40)),
chemokines (IL-8, IP-10, MCP-1, MIP-1α, RANTES and Eotaxin), and regulators of T and
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natural killer cell activation and proliferation (IL-7 and IL-15) in GCF (pg/30s) were
determined as previously described (Thunell 2010) using a commercial multiplexed
fluorescent bead-based immunoassay (Millipore, Billerica, MA) in the Luminex 100 IS
Instrument (Luminex®, Austin, TX). Each sample was assayed in duplicate. Briefly, 50 µl
of 0.01 M PBS, pH 7.2 containing GCF samples were incubated with anti-human multi-
cytokine beads at 4° C for 18 h. Unbound material was removed by filtration. Anti-human
multi-cytokine biotin reporter was added, and reactions were incubated at room temperature
for 1.5 h in the dark. Streptavidin–phycoerythrin then was added, and the plates were
incubated at room temperature for an additional 30 min. Stop solution was added, and the
plates were read in a plate reader (Model 100 IS, Luminex, Austin, TX). Cytokine quantities
in each sample were extrapolated based on standards utilizing Beadview software
(Millipore, Billerica, MA).
Statistical analysis
Analysis of normality was conducted, and nonparametric approaches were used based on the
distribution of the data. Total cytokine amounts (pg/30s) were analyzed and reported for
each cytokine. Cytokine and GCF volumes were analyzed using the Mann-Whitney test to
compare cytokine and GCF levels. This analysis was completed for inter-group and pooled
comparisons. Inter-group comparisons consisted of comparing the healthy controls (Con) to
both healthy and diseased sites in smoking and non-smoking diseased subjects (SH, SD,
NH, ND). Additionally, smokers and non-smokers were compared in relation to healthy and
diseased sites (SH vs NH; SD vs ND). Pooled comparisons consisted of comparing the
healthy controls (Con) to both healthy and diseased sites in pooled smoker and non-smoker
periodontitis subjects (H pooled, D pooled). Intra-group and pooled comparisons for
matched-paired groups were completed using the Wilcoxon matched-pairs signed-rank test.
Intra-group matched-paired comparisons consisted of comparing healthy and diseased sites
in smokers and in non-smokers (SH vs SD; NH vs ND). Pooled matched-paired
comparisons consisted of comparing healthy and diseased sites in diseased subjects (H
pooled vs D pooled). In each case the level of significance was set at p<0.05 (Table 3).
In some subjects, the concentrations of cytokines were beyond the detectable capacity of the
assay, which was 2.3 to 5,000 pg/ml. For those chemokines and cytokines whose
concentrations were below the detectable limit of the immunoassay, a value of 1.3 pg/ml
was assigned by subtracting 1.0 from 2.3 pg/ml, the lowest value of the standard curve.
When the concentrations of cytokines were higher the detectable capacity of the assay, the
samples were diluted and rerun.
Results
Site characteristics among subjects
Diseased sites within the smoking and non-smoking periodontitis groups (SD, ND, D
(pooled) had significantly (p < 0.05) higher values for PD, REC and CAL compared to the
sites in the healthy controls (Con) (Table 2). GCF volumes were significantly higher in both
healthy and diseased sites in periodontitis subjects compared to the healthy controls. (D
pooled vs Con; H (pooled) vs Con, p = 0.0366 and < 0.001, respectively). GCF volumes in
diseased sites of the smoking and non-smoking periodontitis subjects were also significantly
higher (p = 0.0005) than healthy sites (D pooled vs H pooled). Diseased sites within smokers
(SD) showed significantly lower (p = 0.0121) GCF volumes than diseased sites in the non-
smoking population (ND).
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Chemokine and Cytokine Concentrations
Seventeen of the 22 chemokines and cytokines assayed were detected in the GCF, including
IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-12(p40), IL-15, IP-10, IFN-γ, GM-CSF,
MCP-1, MIP-1, RANTES and Eotaxin. The quantities of IL-5, IL-10, IL-12(p70), IL-13,
and TNF-α were below the detectable limits of the multiplex assay. Therefore, they were
excluded from further analysis.
Pro-inflammatory cytokines: IL-1α, IL-1β, IL-6, IL-12(p40), GM-CSF
The quantities of pro-inflammatory cytokines ranged from 0.0 to 32,580.0 pg/30s. The
ranges for IL-1α were the broadest (ranging from 41.5 to 32,580.0 pg/30s), followed by
IL-1β (0.0 to 1,662.0 pg/30s), IL-6 (10.2 to 1,632.0 pg/30s), IL-12(p40) (7.2 to 436.2 pg/
30s), and GM-CSF (0.6 to 130.8 pg/30s) (Figure 1a–e). The significant differences among
the chemokine and cytokine values are presented in Table 3.
Intra-group comparisons—Comparison of healthy and diseased sites in non-smokers
(NH vs. ND) showed significantly higher amounts of IL-1α, IL-1β, IL-12(p40) and GM-
CSF in diseased sites (Figure 1a,b,d,e, Table 3). Diseased sites in the smoking population
(SD) also showed significantly higher quantities of IL-1β than healthy sites (SH) (Figure
1b).
Inter-group comparisons—Healthy sites in non-smokers with periodontitis (NH)
showed significantly higher amounts of IL-1β, IL-6 and IL-12(p40) than the healthy controls
(Con) (Figure 1b–d, Table 3) Diseased sites in the non-smoking population (ND) had
significantly more IL-1α, IL-1β, IL-6 and IL-12(p40) than the healthy controls (Con) (Figure
1a–d, Table 3). Healthy sites in smokers (SH) showed significantly higher quantities of
IL-1β than in healthy controls (Con) (Figure 1b, Table 3). Diseased sites in smokers (SD)
showed significantly higher values for IL-1α and IL-1β than in the healthy controls (Con)
(Figure 1a,b, Table 3). Comparison of healthy sites in smokers and non-smokers (SH vs.
NH) showed significantly less IL-6 and IL-12 (p40) in the smokers (Figure 1c,d, Table 3).
Additionally, diseased sites in smokers (SD) showed significantly less IL-1α, IL-6 and IL-12
(p40) than non-smokers (ND) (Figure 1a,c,d, Table 3).
Pooled comparisons—Diseased sites in pooled periodontitis subjects (D pooled)
demonstrated significantly higher amounts of IL-1α, IL-1β, IL-6, IL-12 (p40) than healthy
sites in periodontitis subjects (H pooled) (Figure 1a–d, Table 3). When compared to healthy
controls (Con), diseased sites in periodontitis subjects (D pooled) showed significantly
greater quantities of IL-1α, IL-1β, IL-6 and IL-12 (p40) (Figure 1a–d, Table 3). Healthy sites
in periodontitis subjects (H pooled) also showed significantly higher IL-1β levels than that
in the healthy controls (Con) (Figure 1b, Table 3).
Chemokines: IL-8, IP-10, MCP-1, MIP-1, RANTES and Eotaxin
Several chemokines were present in the GCF ranging in amounts from 0.6 to 24,306.0 pg/
30s. IL-8 was found in the highest amounts (ranging from 21.2 to 24,306.0 pg/30s). The
remaining chemokines had the following ranges: IP-10 (36.0 to 3,672.0 pg/30s); MIP-1
(18.6 to 573.6 pg/30s); Eotaxin (12.0 to 392.4 pg/30s); RANTES (0.6 to 1,098.0 pg/30s);
and MCP-1 (1.2 to 111.6 pg/30s). The significant differences among the chemokine and
cytokine values are listed Table 4.
Intra-group comparisons—Diseased sites in non-smokers (ND) had significantly higher
amounts of MCP-1 and Eotaxin than healthy sites (NH) (Figure 2c,f, Table 4). In smokers,
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there were no significant differences in any of the chemokines between diseased sites (SD)
when compared to healthy sites (SH) (Figure 2a–f, Table 4).
Inter-group comparisons—Comparison of chemokine amounts in healthy sites of non-
smokers (NH) compared to the healthy controls (Con) showed significantly higher values
for IL-8, MIP-1 and RANTES in NH sites (Figure 2a,d,e Table 4). In contrast, IP-10 showed
significantly lower amounts in the healthy (NH) and diseased (ND) sites of non-smokers
than in the healthy controls (Con) (Figure 2b, Table 4). Comparison of chemokine amounts
in diseased sites of non-smokers (ND) compared to the healthy controls (Con) showed
significantly higher quantities of IL-8, MCP-1, MIP-1, RANTES, and Eotaxin in ND sites
(Figure 2a,c,d,e,f, Table 4).
Healthy (SH) and diseased (SD) sites in smokers showed significantly less IP-10 than the
healthy controls (Con) (Figure 2b, Table 4). Healthy sites in smokers also had lower
amounts of MCP-1 than the healthy controls (Con) (Figure 2c, Table 4). Healthy (SH) and
diseased (SD) sites in the smoking population showed significantly less IL-8, IP-10, MCP-1,
MIP-1α and RANTES than healthy (NH) and diseased sites (ND) of non-smokers with
periodontitis (Figure 2a–e, Table 4).
Pooled comparisons—Diseased sites in pooled periodontitis subjects (D pooled) showed
significantly greater amounts of MCP-1, MIP-1 and RANTES than healthy sites (H) (Figure
2c–e, Table 4). In healthy (H) sites of periodontitis subjects, amounts of IL-8 were
significantly higher than in the healthy controls (Con) (Figure 2a, Table 4). IP-10 was
significantly decreased in both H (pooled) sites and D (pooled) sites compared to healthy
controls (Con) (Figure 2b, Table 4). Diseased (D) sites in periodontitis subjects had
significantly greater levels of IL-8, MIP-1 and RANTES than healthy controls (Con) (Figure
2a,d,e, Table 4).
Th1 and Th2 cytokines: IL-2, IFN-γ, IL-3, and IL-4
Th1 and Th2 cytokines were present but generally were found in low amounts (ranging from
0.0 to 349.2 pg/30s) for all subjects in all groups. The ranges for these cytokines were as
follows: IL-2 (12.2 to 77.4 pg/30s); IFN-γ (0.0 to 152.4 pg/30s);IL-4 (0.6 to 123.0 pg/30s)
and IL-3 (22.2 to 349.2 pg/30s). The GCF from the healthy control group exhibited the
lowest values of each of these 4 cytokines (Figure 3a–d). The significant differences among
the chemokine and cytokine responses are shown in Table 5.
Intra-group comparisons—Comparison of healthy and diseased sites within smokers
(SH vs. SD) and non-smokers (NH vs. ND) showed significantly higher amounts of IFN-γ in
the diseased sites of both groups (Figure 3b, Table 5).
Inter-group comparisons—Diseased sites in non-smokers (ND) showed significantly
greater amounts of IL-2, IFN-γ IL-3, and IL-4 than in the healthy controls (Con) (Figure 3a–
d, Table 5). Diseased sites in the smoking population (SD) showed significantly higher
amounts of IL-3 than in the healthy controls (Con) (Figure 3c, Table 5). Comparisons of
healthy (NH vs. SH) and diseased (ND vs. SD) sites between smokers and non-smokers
showed no significant differences in levels of any Th1 or Th2 cytokine (Figure 3a–d, Table
5).
Pooled comparisons—Diseased sites in pooled periodontitis subjects (D pooled) which
included smokers and nonsmokers demonstrated significantly higher amounts of IFN-γ than
in healthy sites (H pooled) (Figure 3b, Table 3). Additionally, D (pooled) sites also showed
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significantly greater amounts of IL-2, IFN- γ, IL-3 and IL-4 compared to healthy controls
(Con) (Figure 3a–d, Table 3).
Regulators of T-cells and NK cells: IL-7, IL-15
The values for IL-7 in GCF ranged from 21.2 to 196.8 pg/30s, and IL-15 ranged from 10.9
to 48.8 pg/30s (Figure 4a, b). The significant differences among the chemokine and cytokine
responses are found in Table 3.
Intra-group comparisons—No significant differences in amounts of IL-7 or IL-15 were
found when comparing healthy and diseased sites within smokers (SH vs. SD) and non-
smokers (NH vs. ND) (Figure 4a,b, Table 3).
Inter-group comparisons—Healthy (NH) and diseased (ND) sites in non-smokers with
periodontitis showed significantly higher quantities of IL-15 than healthy controls (Con)
(Figure 4a,b, Table 3). Diseased sites in non-smokers (ND) also showed significantly higher
IL-7 than healthy controls (Con) (Figure 4a, Table 3). Comparison of cytokine amounts in
diseased sites of smokers (SD) and non-smokers (ND) showed a significant decrease in IL-7
and IL-15 in smokers (Figure 4a, b, Table 3).
Pooled comparisons—Comparison of healthy (H pooled) and diseased (D pooled) sites
in pooled periodontitis subjects showed significantly higher levels of IL-15 in diseased sites
(Figure 4b, Table 3). Diseased sites in periodontitis subjects (D pooled) also showed
significantly greater amounts of IL-15 when compared to healthy controls (Con) (Figure 4b,
Table 3).
Discussion
The use of the multiplex assay in this study made it possible to evaluate the levels of a
comprehensive panel of cytokines and chemokines in the GCF of periodontally diseased
subjects and healthy controls and the influence of smoking on these parameters. Several
previous studies have evaluated GCF biomarkers in using enzyme-linked immunosorbent
assays (ELISA’s), but a limitation is that this technology can evaluate a limited number of
mediators in each sample. The most important finding of the present study was that smokers
with periodontitis, as compared to nonsmoking periodontitis subjects, exhibited a decrease
in several pro-inflammatory cytokines, chemokines and certain regulators of T-cells and
NK-cells. Consistent with this, there was a higher frequency of differences in biomarker
levels between healthy and diseased sites within nonsmokers than in smokers. Overall,
periodontitis sites (nonsmokers and smokers pooled) and diseased sites in nonsmokers had
significantly elevated cytokine and chemokine profiles as compared to healthy control
subjects.
The Impact of Disease on Biomarker Expression
Within pooled periodontitis subjects, diseased sites as compared to healthy sites contained
elevated amounts of several chemokines and pro-inflammatory cytokines, including IL-1α,
IL-1β, IL-6, IL-12 (p40), MCP-1, MIP-1α and RANTES. IFN-γ, a Th1 cytokine, and IL-15,
a lymphocyte growth factor, were also elevated in these sites. All of these biomarkers as
well as IL-2 IL-3, IL-4 (Th1/Th2 cytokines) and IL-8 were increased in diseased sites in
periodontitis subjects relative to healthy controls.
Numerous studies have shown increased GCF amounts of pro-inflammatory cytokines in
periodontitis, including IL-1 (Teles et al., 2010, Tsai et al., 1995), IL-6 (Geivelis et al.,
1993), and IFN-γ (Dutzan et al., 2009). Interestingly, healthy sites in pooled periodontitis
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subjects exhibited increased IL-1β and IL-8 when compared to healthy control subjects. This
pattern has also been reported by Teles and coworkers (Teles et al., 2010), and Engebretson
et al (Engebretson et al., 2002), where subjects with severe disease had higher levels of
IL-1β in shallow sites compared to subjects with less severe disease. It has been suggested
that this may reflect an overall patient factor such as genotype that influences host response
to bacterial challenge or a pre-clinical stage of inflammation.
Although IL-12 (p40) was elevated in periodontitis subjects, IL-12(p70) was below the
detection level of the assay. IL-12 is a heterodimeric cytokine made up of a 40 kDa (p40)
subunit and a 35 kDa (p35) subunit that comprise the bioactive form, IL-12(p70), which
induces Th1 cell-mediated immunity. The IL-12 p40 subunit is shared by IL-23, another
heterodimeric cytokine that has biological activities similar to, yet distinct from, IL-12
(Belladonna et al., 2002). High amounts of the p40 component inhibit binding of the active
IL-12(p70) to its receptor and therefore inhibit IL-12 bioactivity (Gately et al., 1998).
Reduced levels of the bioactive form of IL-12 in GCF of periodontitis subjects have been
noted by others, with a trend towards decreasing amounts from gingivitis to periodontitis
(Orozco et al., 2006). A relative reduction in bioactive IL-12 could favor the predominant
Th2 response observed in periodontitis. IL-15 is produced by lipopolysaccharide stimulated
fibroblasts, keratinocytes, macrophages and endothelial cells and, similar to the current
study where it was increased in periodontitis sites, it has also been reported to be elevated in
gingivitis sites (Buduneli et al., 2003). Other investigators, however, found that it was lower
in inflamed as compared to healthy tissues (Johnson and Serio, 2007).
Of the chemokines evaluated, IL-8, RANTES, MCP-1 and MIP-1α were elevated in
diseased sites compared to healthy sites in pooled periodontitis subjects (smokers and non-
smokers combined). This is consistent with other studies showing higher GCF IL-8 (Tsai et
al., 1995, Teles et al., 2010, Pradeep et al., 2009), RANTES and/or MCP-1 levels in patients
with aggressive or chronic periodontitis as compared to healthy controls (Emingil et al.,
2004, Kurtis et al., 2005, Pradeep et al., 2009). MIP-1α has not been evaluated in GCF,
although it has been detected in diseased gingival tissues (Gemmell et al., 2001). In non-
periodontal infections, MIP-1α and MCP-1 are consistent with monocyte infiltration that
occurs during infection (Maurer and von Stebut, 2004, Deshmane et al., 2009). IP-10 was
the only marker that was reduced in periodontitis (in both healthy and diseased sites) when
compared to healthy controls. This reduction in diseased sites consistently occurred within
smokers and nonsmokers, as well as between periodontitis subjects and healthy controls.
This unique finding deserves further investigation. IP-10 induction is likely important in
recruiting lymphocytes, cells prominent in periodontal lesions and likely participants in the
adaptive immune response (Taubman and Kawai, 2001). The balance among the various
types of chemokines and their receptors determines the inflammatory and immune cell
profile of the lesion and is proposed to play a role in the balance between disease activity
and stability (Gemmell et al., 2001).
The Impact of Smoking on Biomarker Expression
In this study, smokers exhibited a decrease in several pro-inflammatory cytokines (IL-1α,
IL-6, IL-12(p40)), chemokines (IL-8, IP-10, MCP-1, MIP-1α and RANTES) and regulators
of T-cells and NK cells (IL-7 and IL-15) in diseased sites as compared to diseased sites in
nonsmokers. To our knowledge, a significant decrease in IL-6, IL-7, IL-12(p40), IL-15,
IP-10, MCP-1, MIP-1α and RANTES within smokers has not been previously reported. In
fact, the majority of these biomarkers have not been evaluated before in smokers. In contrast
to the pro-inflammatory cytokines and chemokines, there were no apparent inhibitory effects
of smoking on Th1 and Th2 cytokines.
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Smoking’s inhibition of certain pro-inflammatory cytokines in GCF is supported by other
studies that have shown depressed IL-1α (Petropoulos et al., 2004) and IL-1β (Rawlinson et
al., 2003) in the GCF of smokers with periodontitis compared to nonsmokers with
periodontitis. In contrast, other studies have shown higher GCF levels of IL-1β, IL-6 or
TNF-α in smokers (Zhong et al., 2007, Bostrom et al., 1998, Bostrom et al., 1999) or no
effect of smoking on these mediators (Bostrom et al., 2000, Kamma et al., 2004, Erdemir et
al., 2004). Likewise, in vitro studies of the effects of nicotine or smoke on IL-1β release by
various cell types have yielded conflicting outcomes (Kamer et al., 2006, Wendell and Stein,
2001, Johnson and Organ, 1997, Payne et al., 1996, Bernzweig et al., 1998, de Heens et al.,
2009, Ryder et al., 2002). The majority of studies, however, support a depressive impact of
smoking on IL-1β. These findings underscore how variables such as the model system, the
stimulant (nicotine or smoke), GCF collection techniques and assays used for detection of
biomarker expression contribute to the differences reported in these studies.
Regardless, we observed greater amounts of IL-1α, IL-1β and IL-3 within diseased sites of
smokers when compared to periodontally healthy controls. This relative increase in IL-1β in
diseased smokers is consistent with previous research that found greater total amounts of
IL-1β in smokers with “early-onset” periodontitis as compared to healthy, nonsmoking
control subjects (Kamma et al., 2004). Even though production of pro-inflammatory
biomarkers is depressed in smokers, these mediators still occur at concentrations capable of
pathogenesis.
IL-8 has been extensively evaluated in GCF in smokers. However, the effects of smoking
vary depending on the type of periodontal disease (gingivitis, aggressive or chronic
periodontitis)(Giannopoulou et al., 2003a, Giannopoulou et al., 2003b, Kamma et al., 2004).
Our results demonstrate a reduction of IL-8, MIP-1α, MCP and RANTES in smokers. The
observed reduction in chemokines could contribute to the phenomena of impaired neutrophil
chemotaxis and migration in the periodontium in spite of the presence of leukocytosis
(Palmer et al., 2005).
Recently, others have found that exposure to nicotine suppresses the innate immune
response to infection by reducing the activity of antimicrobial peptides (Radek et al., 2010).
It is possible that a similar phenomenon may occur with the production of chemokines and
cytokines in smokers. Such a situation would help explain the lower amount of chemokines
and cytokines expressed in smokers.
Similar to other studies, smokers in this study had lower GCF volume compared to
nonsmokers (Apatzidou et al., 2005). One might question if this was the primary reason that
smokers showed decreased levels of several of the biomarkers. The data, however, was also
analyzed based on concentration, which takes into consideration GCF volume, and similar
findings were noted. In another study in which smokers and nonsmokers had similar GCF
volumes, the smokers had lower IL-1α concentrations (Petropoulos et al., 2004). Finally,
Cesar-Neto and coworkers reported that both gingival tissue levels mRNA and protein
expression of IL-1α, IL-10, TNF- α were depressed in smokers with periodontitis as
compared to nonsmokers with periodontitis (Cesar-Neto et al., 2007), further supporting a
depressed host response in smokers.
There is generally good correlation between multiplex assays and ELISA’s for most
cytokines in biologic samples; however the multiplex assays may either yield higher or
lower quantitative values, depending on the cytokine being measured (Elshal and McCoy,
2006). Therefore, trends in cytokine expression are similar when comparing the types of
assay, although actual cytokine values may not be directly comparable. Evidence suggests
that these differences are minimized by the use of similar capture and reporter antibodies,
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diluents and serum blockers. The inability to detect TNF-α in the present study may, in part,
be related to these variables. Other investigators have also noted that TNF-α was frequently
undetectable in GCF (Erdemir et al., 2004); furthermore, differences in GCF sampling
techniques contribute to inter-study variation in cytokine values.
The multiplex immunoassay (Luminex®) employed in this study enabled the evaluation of a
comprehensive chemokine and cytokine profile, in both smoking and non-smoking
periodontitis subjects. This is the most comprehensive investigation to date of the impact of
smoking and periodontitis on GCF biomarkers. A key finding was that smokers with
periodontitis, as compared to nonsmoking periodontitis subjects, exhibited a decrease in
several pro-inflammatory cytokines, chemokines and certain regulators of T-cells and NK-
cells. Compared to healthy controls, GCF in subjects with periodontitis contained
significantly higher amounts of the majority of biomarkers evaluated. The nonsmokers
mainly accounted for these findings; compared to the smokers, they had a higher frequency
of elevated biomarker quantities in diseased sites as compared to healthy controls. They also
demonstrated more intra-group differences between healthy and diseased sites.
Smoking inhibited the expression of several biomarkers, including pro-inflammatory
cytokines (IL-1α, IL-6, IL-12 (p40)), chemokines (IL-8, MCP-1, MIP-1α, RANTES) and
regulators of T-cells and NK cells (IL-7, IL-15). The Th1/Th2 cytokines were the only
group of cytokines not decreased by smoking. A reduction of pro-inflammatory cytokines is
consistent with lower levels of clinical inflammation in smokers. Interestingly, levels of
IL-1α and IL-1β at diseased sites in smokers were still elevated relative to periodontally
healthy controls, underscoring the centrality of pro-inflammatory cytokines in the
pathogenesis of periodontal diseases. Chemokine levels in smokers with periodontitis were
not significantly different from the healthy controls, whereas nonsmokers with periodontitis
had elevated chemokines relative to both smokers and the healthy controls. This suggests a
major role for a diminished chemokine response in the pathogenesis of periodontitis in
smokers. An inability to recruit inflammatory and immune cells could lead to an ineffective
defense against periodontal pathogens and increased susceptibility to tissue destruction.
With the progression of our understanding of the pathogenesis of periodontal diseases, we
are better able to identify potential diagnostic biochemical marker(s) that could be used to
predict disease status and/or disease progression. Several studies have evaluated various
cytokines and inflammatory mediators, intracellular and extracellular host enzymes, and
byproducts of tissue breakdown as potential markers of periodontal diseases. The multi-bead
array assay used in this study facilitated characterization of a broad biomarker profile in
smokers and nonsmokers with periodontitis. Future studies assaying these or additional
cytokines using this methodology would improve our understanding of the role of the host
response in periodontitis and smoking’s impact in the inflammatory disease process.
Clinical Relevance
Scientific rationale for the study
The impact of smoking on the host response in periodontitis is not fully understood.
Principal findings
Smokers with periodontitis, as compared to nonsmokers with periodontitis, had decreased
GCF quantities of several pro-inflammatory cytokines, chemokines and key regulators of
T cell function. Within smokers and nonsmokers with periodontitis, GCF from diseased
sites exhibited higher levels of mediators than healthy sites.
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Smoking suppresses the inflammatory and immune response which may contribute to
increased periodontal disease susceptibility in smokers.
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Pro-inflammatory cytokines: Median amounts (pg/30s): a) IL-1α b) IL-1β c) IL-6 d)
IL-12(p40) e) GM-CSF. HC=healthy control; H (pooled) =healthy sites in periodontitis
subjects; D (pooled) =diseased sites in periodontitis subjects; NH=healthy sites in
periodontitis non-smoking subjects; SH=healthy sites in periodontitis smoking subjects;
ND=diseased sites in periodontitis non-smoking subjects; SD=diseased sites in periodontitis
smoking subjects. * p≤0.05, ** p≤0.01, *** p≤0.005, + p≤0.001, ++ p≤0.0005, +++
p≤0.0001.
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Chemokines: Median amounts (pg/30s): a) IL-8 b) IP-10 c) MCP-1 d) MIP-1 e) RANTES f)
Eotaxin. HC=healthy control; H (pooled) =healthy sites in periodontitis subjects; D (pooled)
=diseased sites in periodontitis subjects; NH=healthy sites in periodontitis non-smoking
subjects; SH=healthy sites in periodontitis smoking subjects; ND=diseased sites in
periodontitis non-smoking subjects; SD=diseased sites in periodontitis smoking subjects. *
p≤0.05, ** p≤0.01, *** p≤0.005, + p≤0.001, ++ p≤0.0005, +++ p≤0.0001.
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Th1 and Th2 cytokines: Median amounts (pg/30s): a) IL-2 b) IFN-γ c) IL-3 d) IL-4.
HC=healthy control; H (pooled) =healthy sites in periodontitis subjects; D (pooled)
=diseased sites in periodontitis subjects; NH=healthy sites in periodontitis non-smoking
subjects; SH=healthy sites in periodontitis smoking subjects; ND=diseased sites in
periodontitis non-smoking subjects; SD=diseased sites in periodontitis smoking subjects. *
p≤0.05, ** p≤0.01, *** p≤0.005, + p≤0.001, ++ p≤0.0005, +++ p≤0.0001.
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Regulators of T-cells and NK cells: Median amounts (pg/30s): a) IL-7 b) IL-15 HC=healthy
control, H (pooled)=healthy sites in periodontitis subjects, D (pooled)=diseased sites in
periodontitis subjects, NH=healthy sites in periodontitis non-smoking subjects, SH=healthy
sites in periodontitis smoking subjects, ND=diseased sites in periodontitis non-smoking
subjects, SD=diseased sites in periodontitis smoking subjects. * p≤0.05, ** p≤0.01, ***
p≤0.005, + p≤0.001, ++ p≤0.0005, +++ p≤0.0001.
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Table 1







Age (years, mean ± SEM) 51.2 ± 5.2 51.2 ± 7.4 61.2 ± 9.7
Female 10 8 12
Male 2 12 8















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Clin Periodontol. Author manuscript; available in PMC 2012 March 1.
